TETERBORO, N.J., May 8 /PRNewswire/ -- Quest Diagnostics Incorporated
(NYSE: DGX), the nation's leading provider of diagnostic testing, information
and services, announced that its stockholders had approved an increase in the
number of authorized shares of common stock needed to effect a two-for-one
stock split.
The stock split will be effected by the issuance on May 31, 2001 of a
stock dividend of one new share of common stock for each share of common stock
held by stockholders of record on May 16, 2001. The company has approximately
47 million shares of common stock outstanding and previously its charter had
authorized the issuance of 100 million shares of common stock. Stockholders
approved an amendment to the company's certificate of incorporation to
increase the authorization to 300 million shares of common stock at the
company's 2001 Annual Meeting of Stockholders, held this morning in New York
City. Following the dividend, the company will have approximately 94 million
shares of common stock outstanding.
In addition, Quest Diagnostics announced that Kenneth W. Freeman, Chairman
and Chief Executive Officer, is scheduled to speak at the Deutsche Banc Alex.
Brown Health Care 2001 Conference on Thursday, May 10, 2001 in Baltimore. The
Quest Diagnostics presentation is scheduled to begin at approximately 9:00
a.m. Eastern Time. The public is invited to listen to a live webcast of the
presentation on the Internet by visiting the following web address:
http://www.db.com/conferences. A replay of the webcast will be available for
90 days following the conference.
Quest Diagnostics is the nation's leading provider of diagnostic testing,
information and services with annual revenues of $3.4 billion in 2000. The
company's diagnostic testing yields information that enables health care
professionals and consumers to make better decisions to improve health. Quest
Diagnostics offers patients and physicians the broadest access to diagnostic
testing services through its national network of approximately 30 full-service
laboratories, 150 rapid response laboratories and more than 1,300 patient
service centers, where specimens are collected. Quest Diagnostics is the
leading provider of esoteric testing, including gene-based testing, and is the
leader in routine medical testing, drugs of abuse testing, and anatomic
pathology testing. Through partnerships with pharmaceutical, biotechnology and
information technology companies, Quest Diagnostics provides support to help
speed the development of health care insights and new therapeutics. Additional
company information can be found on the Internet at:
http://www.questdiagnostics.com.
The statements in this press release which are not historical facts or
information may be forward-looking statements. These forward-looking
statements involve risks and uncertainties that could cause the outcome to be
materially different. Certain of these risks and uncertainties are described
in the Quest Diagnostics Incorporated 2000 Form 10-K and subsequent filings.
MAKE YOUR OPINION COUNT -- Click Here
http://tbutton.prnewswire.com/prn/11690X66270657
SOURCE Quest Diagnostics Incorporated
CONTACT: Media - Gary Samuels, 201-393-5700, or Investors - Cathy
Doherty, 201-393-5030, both of Quest Diagnostics Incorporated/